Efficacy of Radiotherapy on Intermediate and Advanced Lung Cancer and Its Effect on Dynamic Changes of Serum Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Jun 22

PMID 29928404

Citations 3

Authors

Guowei Ding

Yongchao Liu

Chunmei Liang

Affiliations

Soon will be listed here.

Abstract

The present study intended to investigate efficacy of radiotherapy in the treatment of intermediate and advanced stage lung cancer and the effects on serum vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9). Serum levels of VEGF and MMP-9 of 77 patients with intermediate or advanced lung cancer were detected before and after the treatment. At the same time, 19 healthy people were selected as the control group. Gelatin zymography was applied to measure the activity of serum MMP-9, ELISA was performed to detect the VEGF and MMP-9 levels in the peripheral blood and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to measure the messenger RNA (mRNA) levels of VEGF and MMP-9 in serum. Results indicated that the overall response rate of radiotherapy on intermediate and advanced lung cancer reached 70.1%. Levels of serum VEGF and MMP-9 in the effective treatment group were significantly lower than those before the treatment (P<0.05). Furthermore, expression levels of VEGF and MMP-9 in the effective radiotherapy group were significantly lower than those in ineffective group (P<0.05), MMP-9 activity before treatment was significantly higher than that after treatment (P<0.05) and expression levels of VEGF and MMP-9 mRNA before treatment were significantly elevated compared with those after treatment (P<0.05). The results suggested that the expression levels of serum VEGF and MMP-9 may be useful indicators for the evaluation of the efficacy of radiotherapy in the treatment of intermediate and advanced lung cancer.

Citing Articles

Combined Radiochemotherapy: Metalloproteinases Revisited.

Waller V, Pruschy M Front Oncol. 2021; 11:676583.

PMID: 34055644 PMC: 8155607. DOI: 10.3389/fonc.2021.676583.

Effects of ultrasound-guided paravertebral block on MMP-9 and postoperative pain in patients undergoing VATS lobectomy: a randomized, controlled clinical trial.

Chu H, Dong H, Wang Y, Niu Z BMC Anesthesiol. 2020; 20(1):59.

PMID: 32143570 PMC: 7059262. DOI: 10.1186/s12871-020-00976-1.

Matrix metalloproteases and TIMPs as prognostic biomarkers in breast cancer patients treated with radiotherapy: A pilot study.

Olivares-Urbano M, Grinan-Lison C, Zurita M, Del Moral R, Rios-Arrabal S, Artacho-Cordon F J Cell Mol Med. 2019; 24(1):139-148.

PMID: 31568637 PMC: 6933337. DOI: 10.1111/jcmm.14671.

References

Farhat F, Tfayli A, Fakhruddin N, Mahfouz R, Otrock Z, Alameddine R . Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol. 2012; 84(2):149-60. DOI: 10.1016/j.critrevonc.2012.02.012. View

Fan Z, Duan X, Cai H, Wang L, Li M, Qu J . Curcumin inhibits the invasion of lung cancer cells by modulating the PKCα/Nox-2/ROS/ATF-2/MMP-9 signaling pathway. Oncol Rep. 2015; 34(2):691-8. DOI: 10.3892/or.2015.4044. View

Kerenidi T, Kazakou A, Lada M, Tsilioni I, Daniil Z, Gourgoulianis K . Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9. Cancer Invest. 2016; 34(8):385-92. DOI: 10.1080/07357907.2016.1223301. View

Yeo C, Kim Y, Lee H, Kim J, Lee S, Kim S . Inhibiting IGF-1R attenuates cell proliferation and VEGF production in IGF-1R over-expressing EGFR mutant non-small cell lung cancer cells. Exp Lung Res. 2017; 43(1):29-37. DOI: 10.1080/01902148.2017.1282994. View

Hayano K, Kulkarni N, Duda D, Heist R, Sahani D . Exploration of Imaging Biomarkers for Predicting Survival of Patients With Advanced Non-Small Cell Lung Cancer Treated With Antiangiogenic Chemotherapy. AJR Am J Roentgenol. 2016; 206(5):987-93. DOI: 10.2214/AJR.15.15528. View

Ramanujum R, Lin Y, Liu J, He S . Regulatory expression of MMP-8/MMP-9 and inhibition of proliferation, migration and invasion in human lung cancer A549 cells in the presence of HGF variants. Kaohsiung J Med Sci. 2013; 29(10):530-9. DOI: 10.1016/j.kjms.2013.01.011. View

Balla M, Desai S, Purwar P, Kumar A, Bhandarkar P, Shejul Y . Differential diagnosis of lung cancer, its metastasis and chronic obstructive pulmonary disease based on serum Vegf, Il-8 and MMP-9. Sci Rep. 2016; 6:36065. PMC: 5095766. DOI: 10.1038/srep36065. View

Xu L, Lina W, Xuejun Y . The diagnostic value of serum CEA, NSE and MMP-9 for on-small cell lung cancer. Open Med (Wars). 2017; 11(1):59-62. PMC: 5329799. DOI: 10.1515/med-2016-0012. View

Matsumoto Y, Zhang Q, Akita K, Nakada H, Hamamura K, Tsuchida A . Trimeric Tn antigen on syndecan 1 produced by ppGalNAc-T13 enhances cancer metastasis via a complex formation with integrin α5β1 and matrix metalloproteinase 9. J Biol Chem. 2013; 288(33):24264-76. PMC: 3745370. DOI: 10.1074/jbc.M113.455006. View

10.

Zheng H, Liu J . Studies on the relationship between P13K/AKT signal pathway-mediated MMP-9 gene and lung cancer. Eur Rev Med Pharmacol Sci. 2017; 21(4):753-759. View

11.

Cai J, Li R, Xu X, Zhang L, Wu S, Yang T . URGCP promotes non-small cell lung cancer invasiveness by activating the NF-κB-MMP-9 pathway. Oncotarget. 2015; 6(34):36489-504. PMC: 4742191. DOI: 10.18632/oncotarget.5351. View

12.

Zhang H, Yun S, Batuwangala T, Steward M, Holmes S, Pan L . A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment. Int J Cancer. 2011; 131(4):956-69. DOI: 10.1002/ijc.26427. View

13.

Kim A, Im M, Yim N, Ma J . Reduction of metastatic and angiogenic potency of malignant cancer by Eupatorium fortunei via suppression of MMP-9 activity and VEGF production. Sci Rep. 2014; 4:6994. PMC: 4227014. DOI: 10.1038/srep06994. View

14.

Peng W, Zhang J, Wang B, Pan H, Lu M, Wang J . Prognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancer. Clin Chim Acta. 2012; 413(13-14):1121-6. DOI: 10.1016/j.cca.2012.03.012. View

15.

Shiau M, Fan L, Yang S, Tsao C, Lee H, Cheng Y . Human papillomavirus up-regulates MMP-2 and MMP-9 expression and activity by inducing interleukin-8 in lung adenocarcinomas. PLoS One. 2013; 8(1):e54423. PMC: 3549962. DOI: 10.1371/journal.pone.0054423. View

16.

Lin X, Li H, Lin X, Yu M, Tu X, Hua Z . Silencing of Livin inhibits tumorigenesis and metastasis via VEGF and MMPs pathway in lung cancer. Int J Oncol. 2015; 47(2):657-67. DOI: 10.3892/ijo.2015.3058. View

17.

Liu F, Zhu L . [Expression of adiponectin in non-small cell lung cancer and its relationship with MMP-9 and angiogenesis]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2015; 40(6):579-84. DOI: 10.11817/j.issn.1672-7347.2015.06.002. View

18.

Ye H, Bai J, Guo P, Wang W, Lin C . [Propofol suppresses invasion of human lung cancer A549 cells by down-regulating aquaporin-3 and matrix metalloproteinase-9]. Nan Fang Yi Ke Da Xue Xue Bao. 2016; 36(9):1286-1290. View

19.

Lee C, Shim H, Lee S, Lee J, Kim D, Chung K . Prognostic effect of matrix metalloproteinase-9 in patients with resected Non small cell lung cancer. J Cardiothorac Surg. 2015; 10:44. PMC: 4379698. DOI: 10.1186/s13019-015-0248-3. View

20.

El-Badrawy M, Yousef A, Shaalan D, Elsamanoudy A . Matrix metalloproteinase-9 expression in lung cancer patients and its relation to serum mmp-9 activity, pathologic type, and prognosis. J Bronchology Interv Pulmonol. 2014; 21(4):327-34. DOI: 10.1097/LBR.0000000000000094. View